ArticleJournal of the American Heart Association2025
Cardiovascular Disease Attributable to High Systolic Blood Pressure in Younger Adults Requires Greater Attention: Insights from the Global Burden of Disease Study 2021.
Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Cardiac Organ Damage in Young Adults with Cryptogenic Ischaemic Stroke: The SECRETO Study.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2026Article
- Sex-Specific Prospective Association of Serum Zinc Concentration with Cardiovascular Disease and Mortality: A 10-Year Population-Based Cohort Study.Journal of cardiovascular translational research · 2026Article
- Model Analysis of the American Heart Association's Life's Essential 8: Can Physical Activity Mitigate Cardiovascular Risk Among Low-Income Individuals?Journal of the American Heart Association · 2026Article
- Association between urinary antibiotic exposure and blood pressure parameters in reproductive-age men: a biomonitoring-based cross-sectional study in China.Translational andrology and urology · 2026Article
- Pattern of Healthcare Utilization Related to Hypertension and Associated Factors: A Survey Study in the Capital of Iran.Medical journal of the Islamic Republic of Iran · 2026Article
- Hypertension prevalence in the Asia-Pacific region: a systematic analysis of population-based studies.Journal of pharmaceutical policy and practice · 2026Article
- Retrospective cohort study assessing cardiovascular risk reduction through intensive blood pressure management in high-risk patients.Frontiers in cardiovascular medicine · 2026Article
- Hypertension-attributable stroke burden in younger vs older people: analysis of GBD 2021 and NHANES databases.American journal of preventive cardiology · 2025Article
- Comparative Effectiveness of SGLT2i and GLP-1RA on Blood Pressure in Hypertensive Patients with Type 2 Diabetes: A Saudi Multicenter Retrospective Study.Journal of clinical medicine · 2025Article
- Editorial: Advances in diabetes and hypertension research.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCardiovascular disease (CVD) represents the most significant global burden among all diseases. High systolic blood pressure (HBP) is the most prevalent risk factor for CVD. This study aims to investigate the global burden of CVDs attributable to high systolic blood pressure (HBP-CVD) and to assess the effectiveness of disease control across different age groups.
methodsThe burden was assessed by analyzing the numbers, age-standardized rates of deaths, and disability-adjusted life-years, alongside the corresponding estimated annual percentage change, stratified by age, sex, sociodemographic index, and geographical regions.
resultsFrom 1990 to 2021, the age-standardized rates of death and disability-adjusted life-years declined, with estimated annual percentage changes of -1.45 and -1.36, respectively. However, owing to the growth in population, the current burden of HBP-CVD is increasing. The age-period-cohort model suggests that the alleviation of disease burden is more pronounced in populations ≥50 years of age, with the lowest point occurring around 70 years of age. The age-stratified estimated annual percentage change further substantiates this issue, revealing that disease control efforts are least effective in the 15 to 49 years of age group, compared with the 50 to 69 and 70+ years of age groups. Overall, health inequities in HBP-CVD are decreasing, yet they persist. More importantly, health inequities in the 15 to 49 years of age group have exacerbated from 1990 to 2021.
conclusionsThe burden of HBP-CVD remains severe, and disease control was least effective in the 15 to 49 years of age group compared with the 50 to 69 and 70+ years of age groups. Urgent adjustments to health care policies are imperative.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.